Switch theme
Sign up to access all valuation multiples
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
2008
2.4K+
LTM Revenue $2.9B
LTM EBITDA $356M
$31.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
argenx has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $356M.
In the most recent fiscal year, argenx achieved revenue of $2.5B and an EBITDA of $118M.
argenx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See argenx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.5B | XXX | XXX | XXX |
| Gross Profit | $2.6B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $356M | XXX | $118M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBIT | $309M | XXX | -$20.0M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | $860M | XXX | $936M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 38% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, argenx's stock price is EUR 506 (or $569).
argenx has current market cap of EUR 30.9B (or $34.7B), and EV of EUR 28.0B (or $31.4B).
See argenx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31.4B | $34.7B | XXX | XXX | XXX | XXX | $13.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, argenx has market cap of $34.7B and EV of $31.4B.
argenx's trades at 12.8x EV/Revenue multiple, and 266.1x EV/EBITDA.
Equity research analysts estimate argenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
argenx has a P/E ratio of 40.4x.
See valuation multiples for argenx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $34.7B | XXX | $34.7B | XXX | XXX | XXX |
| EV (current) | $31.4B | XXX | $31.4B | XXX | XXX | XXX |
| EV/Revenue | 10.8x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBITDA | 88.3x | XXX | 266.1x | XXX | XXX | XXX |
| EV/EBIT | 101.8x | XXX | -1568.3x | XXX | XXX | XXX |
| EV/Gross Profit | 12.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.4x | XXX | 37.1x | XXX | XXX | XXX |
| EV/FCF | -163.5x | XXX | -185.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trialargenx's last 12 month revenue growth is 39%
argenx's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.9M for the same period.
argenx's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
argenx's rule of X is 110% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for argenx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 217% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 110% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
argenx acquired XXX companies to date.
Last acquisition by argenx was XXXXXXXX, XXXXX XXXXX XXXXXX . argenx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was argenx founded? | argenx was founded in 2008. |
| Where is argenx headquartered? | argenx is headquartered in Belgium. |
| How many employees does argenx have? | As of today, argenx has 2.4K+ employees. |
| Who is the CEO of argenx? | argenx's CEO is Mr. Tim Van Hauwermeiren, M. Sc.. |
| Is argenx publicy listed? | Yes, argenx is a public company listed on BRU. |
| What is the stock symbol of argenx? | argenx trades under ARGX ticker. |
| When did argenx go public? | argenx went public in 2014. |
| Who are competitors of argenx? | Similar companies to argenx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of argenx? | argenx's current market cap is $34.7B |
| What is the current revenue of argenx? | argenx's last 12 months revenue is $2.9B. |
| What is the current revenue growth of argenx? | argenx revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of argenx? | Current revenue multiple of argenx is 10.8x. |
| Is argenx profitable? | Yes, argenx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of argenx? | argenx's last 12 months EBITDA is $356M. |
| What is argenx's EBITDA margin? | argenx's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of argenx? | Current EBITDA multiple of argenx is 88.3x. |
| What is the current FCF of argenx? | argenx's last 12 months FCF is -$192M. |
| What is argenx's FCF margin? | argenx's last 12 months FCF margin is -7%. |
| What is the current EV/FCF multiple of argenx? | Current FCF multiple of argenx is -163.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
